Open access
Open access
Powered by Google Translator Translator

Oncology – Gastrointestinal

Preliminary results of a RCT | Once-only colonoscopy vs. two rounds of fecal immunochemical testing 2 years apart for colorectal cancer screening.

20 Sep, 2022 | 13:29h | UTC

Once-only colonoscopy or two rounds of faecal immunochemical testing 2 years apart for colorectal cancer screening (SCREESCO): preliminary report of a randomised controlled trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)

Commentary: Two Rounds of FIT vs Single Colonoscopy as a One-time CRC Screening – Medscape (free registration required)

 


RCT | Short-term outcomes of laparoscopy-assisted vs. open surgery for patients with low rectal cancer.

16 Sep, 2022 | 12:58h | UTC

Short-term Outcomes of Laparoscopy-Assisted vs Open Surgery for Patients With Low Rectal Cancer: The LASRE Randomized Clinical Trial – JAMA Oncology

 

Commentary on Twitter

 


RCT | Robotic vs. laparoscopic surgery for middle and low rectal cancer.

15 Sep, 2022 | 13:09h | UTC

Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)

Commentaries:

Robotic Surgery Tops Laparoscopic Surgery for Middle and Low Rectal Cancer — Randomized trial shows fewer positive circumferential resection margins with robotic technique – MedPage Today (free registration required)

 

Commentaries on Twitter

 


RCT | Extended duration thromboprophylaxis (continued for 56 days postoperatively) is not beneficial after surgical resection of colorectal cancer.

14 Sep, 2022 | 13:22h | UTC

Efficacy and safety of extended duration to perioperative thromboprophylaxis with low molecular weight heparin on disease-free survival after surgical resection of colorectal cancer (PERIOP-01): multicentre, open label, randomised controlled trial – The BMJ

 


AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma.

11 Sep, 2022 | 22:50h | UTC

AASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma – Hepatology

 


RCT | Ripretinib vs. Sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib.

8 Sep, 2022 | 14:24h | UTC

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial – Journal of Clinical Oncology

Editorial: Ripretinib and the Failure to Advance GI Stromal Tumor Therapy in the Age of Precision Medicine – Journal of Clinical Oncology

 

Commentary on Twitter

 


Single-arm, phase 2 study | Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.

6 Sep, 2022 | 14:24h | UTC

Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentaries:

Addition of Galunisertib to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer – The ASCO Post

Improved Complete Response Rate Observed With Galunisertib Plus Neoadjuvant CRT in Advanced Rectal Cancer – Cancer Network

 


5-year follow-up of a RCT | Five-year outcomes of FOLFIRINOX vs. Gemcitabine as adjuvant therapy for pancreatic cancer.

5 Sep, 2022 | 14:26h | UTC

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Systematic Review | Contrast‐enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

5 Sep, 2022 | 14:13h | UTC

Contrast‐enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease – Cochrane Library

Summary: How accurate are contrast-enhanced ultrasound scans for detecting hepatocellular carcinoma? – Cochrane Library

 


Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score

2 Sep, 2022 | 13:03h | UTC

Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score – ESMO Open

 


Single-arm phase 2 study | Neoadjuvant Nivolumab plus Ipilimumab and Adjuvant Nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma.

1 Sep, 2022 | 11:47h | UTC

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study – Journal of Clinical Oncology

 


Guideline | Fecal immunochemical testing in patients with signs or symptoms of suspected colorectal cancer.

31 Aug, 2022 | 11:52h | UTC

Faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer (CRC): a joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the British Society of Gastroenterology (BSG) – Gut

Commentary: Guidelines update: use of FIT in colorectal cancer referrals – PULSE

 


Meta analysis of randomized trials | Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer.

30 Aug, 2022 | 12:07h | UTC

Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials – JAMA Oncology (free for a limited period)

 

Commentary on Twitter

 


RCT | Colorectal Endoscopic Stenting Trial (CReST) for obstructing left-sided colorectal cancer.

30 Aug, 2022 | 11:58h | UTC

Colorectal Endoscopic Stenting Trial (CReST) for obstructing left-sided colorectal cancer: randomized clinical trial – British Journal of Surgery

 


Cohort Study | Outcomes of patients with sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm under active surveillance.

30 Aug, 2022 | 11:57h | UTC

Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial – British Journal of Surgery

 


Clinical practice guidelines for intrahepatic cholangiocarcinoma.

26 Aug, 2022 | 13:20h | UTC

Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma – Liver Cancer

 


Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus.

26 Aug, 2022 | 13:19h | UTC

Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition) – Liver Cancer

 


Network M-A | Efficacy of various adjuvant chemotherapy methods in preventing liver metastasis from potentially curative colorectal cancer.

25 Aug, 2022 | 12:01h | UTC

Efficacy of various adjuvant chemotherapy methods in preventing liver metastasis from potentially curative colorectal cancer: A systematic review network meta-analysis of randomized clinical trials – Cancer Medicine

 


Review | New concepts in the treatment of hepatocellular carcinoma.

24 Aug, 2022 | 13:56h | UTC

New concepts in the treatment of hepatocellular carcinoma – UEG Journal

 


Case-control study | Assessment of outcomes from 1-year surveillance after detection of early gastric cancer among patients at high risk.

23 Aug, 2022 | 13:11h | UTC

Assessment of Outcomes From 1-Year Surveillance After Detection of Early Gastric Cancer Among Patients at High Risk in Japan – JAMA Network Open

Commentary: Intensive Endoscopy Might Not Be One-and-Done for Gastric Cancer Surveillance — High-risk group had similar new lesion detection rates initially and at 15 months – MedPage Today (free registration required)

 

Commentary on Twitter

 


Single-arm Phase 2 study | Neoadjuvant chemotherapy, excision, and observation for early rectal cancer.

23 Aug, 2022 | 12:53h | UTC

Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results – Journal of Clinical Oncology

 

Commentary from the author on Twitter (thread – click for more)

 


RCT | Effectiveness of Etoposide and Cisplatin vs. Irinotecan and Cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system.

22 Aug, 2022 | 11:54h | UTC

Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial – JAMA Oncology

 

Commentary on Twitter

 


Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.

18 Aug, 2022 | 12:47h | UTC

Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies – ESMO Open

Commentaries:

Prompt recognition and treatment found effective for lung disease in patients who received new drug for advanced cancer – The Mount Sinai Health System

Trastuzumab deruxtecan-related ILD/pneumonitis characterized – medwire News

Related: Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review – Drugs

 


Review | Barrett Esophagus.

17 Aug, 2022 | 14:26h | UTC

Barrett Esophagus: A Review – JAMA (free for a limited period)

Audio clinical review: Barrett Esophagus – JAMA

Related: Diagnosis and Management of Barrett’s Esophagus: An Updated ACG Guideline – American Journal of Gastroenterology

 


M-A | Use of folic acid supplementation to halt and even reverse the progression of gastric precancerous conditions.

11 Aug, 2022 | 11:51h | UTC

Use of folic acid supplementation to halt and even reverse the progression of gastric precancerous conditions: a meta-analysis – BMC Gastroenterology

Commentary: Can Folic Acid Halt or Reverse Progression of Gastric Precancerous Conditions? – Medscape (free registration required)

 


Stay Updated in Your Specialty

No spam, just news.